Parkinson's disease is a neurodegenerative disorder characterized by the degenerationdopamine-producingcing neurons. The gold standard therfory of the diseasethe is administration of levodopa/cawhichopa that aims to replenish the missing dopamine in the brain of patients. When orally taken levodopa causes pulsatile no physiologic stimulation of dopaminergic neurons in the brain, which is believed to be the cause of the appearalevodopa-inducedinduced motor complications such as on-off fluctuations and dyskinesias. It is believed that continuous levodopa administration that will mimic a more physiological stimulation is the key to decreasing these motor complications. The available medications that provide continuous levodopa administration are levodopa intestinal gel infusion (Duodopa,) , ND0612 and Rytary (IPX066) that already show improvement in the motor complications of prolonged levodopa use in patients with Parkinson's disease.